// App-Quantinova.ai

P281 : 52-Week efficacy and safety of ixekizumab in r-axSpA/AS patients naïve to biologic treatments or with prior inadequate response/intolerance to tumor necrosis factor inhibitors

Researchers

Presenter

  • Karl Gaffney

Principal Investigators

  • Daniel Aletaha

  • Andrew J Bradley

  • Mani H Nassab

  • Soy Liu Leage

  • Raphael Micheroli

Medical Centers

  • Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UNITED KINGDOM

  • Eli Lilly and Company, Eli Lilly and Company, Indianapolis, IN

  • Klinik für Rheumatologie, Universitätsspital Zürich, Zurich, SWITZERLAND

Locations

  • United Kingdom

  • Austria

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Inflammatory Arthritis

  • Axial spondyloarthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • III

Study Id's

  • NCT02696785

  • NCT02696798

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved